<?xml version='1.0' encoding='utf-8'?>
<document id="27406852"><sentence text="Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients."><entity charOffset="13-24" id="DDI-PubMed.27406852.s1.e0" text="acylpeptide" /><entity charOffset="52-65" id="DDI-PubMed.27406852.s1.e1" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.27406852.s1.e0" e2="DDI-PubMed.27406852.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27406852.s1.e0" e2="DDI-PubMed.27406852.s1.e1" /></sentence><sentence text="Concomitant use of meropenem (MEPM) can dramatically decrease valproic acid (VPA) plasma level"><entity charOffset="19-28" id="DDI-PubMed.27406852.s2.e0" text="meropenem" /><entity charOffset="30-34" id="DDI-PubMed.27406852.s2.e1" text="MEPM" /><entity charOffset="62-75" id="DDI-PubMed.27406852.s2.e2" text="valproic acid" /><entity charOffset="77-80" id="DDI-PubMed.27406852.s2.e3" text="VPA" /><pair ddi="false" e1="DDI-PubMed.27406852.s2.e0" e2="DDI-PubMed.27406852.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27406852.s2.e0" e2="DDI-PubMed.27406852.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27406852.s2.e0" e2="DDI-PubMed.27406852.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27406852.s2.e0" e2="DDI-PubMed.27406852.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27406852.s2.e1" e2="DDI-PubMed.27406852.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27406852.s2.e1" e2="DDI-PubMed.27406852.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27406852.s2.e1" e2="DDI-PubMed.27406852.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27406852.s2.e2" e2="DDI-PubMed.27406852.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27406852.s2.e2" e2="DDI-PubMed.27406852.s2.e3" /></sentence><sentence text=" It is accepted that inhibition in acylpeptide hydrolase (APEH) activity by MEPM coadministration was the trigger of this drug-drug interaction"><entity charOffset="76-78" id="DDI-PubMed.27406852.s3.e0" text="MEPM" /></sentence><sentence text="" /><sentence text="To investigate the influence of APEH genetic polymorphisms on VPA plasma concentration in Chinese epilepsy patients"><entity charOffset="62-65" id="DDI-PubMed.27406852.s5.e0" text="VPA" /></sentence><sentence text="" /><sentence text="Urinary VPA-d6 β-D-glucuronide concentration was determined in 19 patients with VPA treatment alone (n = 10) or concomitant use with MEPM (n = 9)"><entity charOffset="80-83" id="DDI-PubMed.27406852.s7.e0" text="VPA" /><entity charOffset="133-135" id="DDI-PubMed.27406852.s7.e1" text="MEPM" /><entity charOffset="8-10" id="DDI-PubMed.27406852.s7.e2" text="VPA" /><pair ddi="false" e1="DDI-PubMed.27406852.s7.e2" e2="DDI-PubMed.27406852.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27406852.s7.e2" e2="DDI-PubMed.27406852.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27406852.s7.e2" e2="DDI-PubMed.27406852.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27406852.s7.e0" e2="DDI-PubMed.27406852.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27406852.s7.e0" e2="DDI-PubMed.27406852.s7.e1" /></sentence><sentence text=" A retrospective study was performed on 149 epilepsy patients to investigate the influence of APEH polymorphisms rs3816877 and rs1131095 on adjusted plasma VPA concentration (CVPA) at steady-state"><entity charOffset="156-158" id="DDI-PubMed.27406852.s8.e0" text="VPA" /><entity charOffset="176-178" id="DDI-PubMed.27406852.s8.e1" text="VPA" /><pair ddi="false" e1="DDI-PubMed.27406852.s8.e0" e2="DDI-PubMed.27406852.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27406852.s8.e0" e2="DDI-PubMed.27406852.s8.e1" /></sentence><sentence text="" /><sentence text="Urinary VPA-d6 β-D-glucuronide (VPA-G) concentration was increased significantly in patients with MEPM coadministration"><entity charOffset="32-37" id="DDI-PubMed.27406852.s10.e0" text="VPA-G" /><entity charOffset="98-102" id="DDI-PubMed.27406852.s10.e1" text="MEPM" /><entity charOffset="8-12" id="DDI-PubMed.27406852.s10.e2" text="VPA" /><pair ddi="false" e1="DDI-PubMed.27406852.s10.e2" e2="DDI-PubMed.27406852.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27406852.s10.e2" e2="DDI-PubMed.27406852.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27406852.s10.e2" e2="DDI-PubMed.27406852.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27406852.s10.e0" e2="DDI-PubMed.27406852.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27406852.s10.e0" e2="DDI-PubMed.27406852.s10.e1" /></sentence><sentence text=" The CVPA of patients carrying the APEH rs3816877 C/C genotype was significantly higher than that of C/T carriers, and the difference was still obvious when stratified by UGT2B7 rs7668258 polymorphism"><entity charOffset="6-8" id="DDI-PubMed.27406852.s11.e0" text="VPA" /></sentence><sentence text="" /><sentence text="APEH polymorphism has significant influence on VPA pharmacokinetics in Chinese population"><entity charOffset="47-49" id="DDI-PubMed.27406852.s13.e0" text="VPA" /></sentence><sentence text="" /></document>